Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas

NCT02859402 is registered in ClinicalTrials.gov with Keimyung University Dongsan Medical Center as lead sponsor.

NCT NCT02859402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas
Lead sponsor
Keimyung University Dongsan Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
December 31, 2016
Completion date
December 31, 2027
Enrollment
34 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, extranodal nk-t-cell, t-cell non-hodgkin lymphoma